What is ospemifene (Osphena) for vaginal atrophy?
Ospemifene (Osphena) is a non-hormonal oral medication for the treatment of moderate to severe vaginal atrophy, particularly in women who cannot use oestrogen. It acts as a selective oestrogen receptor modulator (SERM) to improve vaginal health and reduce pain during sex.
Detailed Medical Explanation
Ospemifene binds to oestrogen receptors in vaginal tissues, stimulating tissue growth and moisture without the risks associated with oestrogen therapy. Clinical trials show improved vaginal pH, elasticity, and reduced pain with intercourse. It is not available on the NHS but may be considered for those unable to use other therapies. Side effects may include hot flushes and rare blood clot risk. NHS: Ospemifene.
Clinical Context
Ospemifene offers an option for women needing a non-oestrogen systemic therapy for atrophy, under specialist supervision.
Evidence-Based Approaches
Ospemifene is supported by international guidelines as a secondary option for moderate-severe atrophy when local therapy is not suitable. RCOG: SERM Therapy.